Zoledronic acid in pediatric metabolic bone disorders

被引：30

作者：

Bowden, Sasigarn A. ^{[1
]}

Mahan, John D. ^{[2
]}

机构：

[1] Ohio State Univ, Dept Pediat, Coll Med, Div Endocrinol,Nationwide Childrens Hosp, Columbus, OH 43210 USA

[2] Ohio State Univ, Dept Pediat, Coll Med, Div Nephrol,Nationwide Childrens Hosp, Columbus, OH 43210 USA

来源：

TRANSLATIONAL PEDIATRICS | 2017年 / 6卷 / 04期

关键词：

Zoledronic acid (ZA); osteoporosis; fragility fractures; bone mineral density (BMD); metabolic bone disease; hypercalcemia; osteonecrosis (ON); acute phase reaction (APR); SEVERE CEREBRAL-PALSY; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; INTRAVENOUS BISPHOSPHONATE THERAPY; ACUTE LYMPHOBLASTIC-LEUKEMIA; DUCHENNE MUSCULAR-DYSTROPHY; ACUTE-PHASE RESPONSE; SHORT-TERM SAFETY; OSTEOGENESIS-IMPERFECTA; MINERAL DENSITY; PHARMACOLOGICAL PROFILE;

D O I：

10.21037/tp.2017.09.10

中图分类号：

R72 [儿科学];

学科分类号：

100202 [儿科学];

摘要：

Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted.

引用

页码：256 / 268

页数：13

共 79 条

[1]

Allington Nanni, 2005, Acta Orthop Belg, V71, P91

[2]

Bone involvement in sickle cell disease [J].

Almeida, A ;

Roberts, I .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (04) :482-490

[3]

Atance EPalomo, 2011, ANALES PEDIAT

[4]

The Use of Zoledronic Acid in Pediatric Cancer Patients [J].

August, Keith J. ;

Dalton, Amanda ;

Katzenstein, Howard M. ;

George, Bradley ;

Olson, Thomas A. ;

Wasilewski-Masker, Karen ;

Rapkin, Louis B. .

PEDIATRIC BLOOD & CANCER, 2011, 56 (04) :610-614

[5]

Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta [J].

Barros, Elizabete Ribeiro ;

Saraiva, Gabriela L. ;

de Oliveira, Telma Palomo ;

Lazaretti-Castro, Marise .

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2012, 25 (5-6) :485-491

[6]

Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy [J].

Bell, Jennifer M. ;

Shields, Michael D. ;

Watters, Janet ;

Hamilton, Alistair ;

Beringer, Timothy ;

Elliott, Mark ;

Quinlivan, Rosaline ;

Tirupathi, Sandya ;

Blackwood, Bronagh .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01)

[7]

Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO

[8]

2-0

[9]

Glucorticoids and bone: Some general remarks and some special observations in pediatric patients [J].

Bianchi, ML .

CALCIFIED TISSUE INTERNATIONAL, 2002, 70 (05) :384-390

[10]

Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen [J].

Biggin, Andrew ;

Briody, Julie N. ;

Ormshaw, Elizabeth ;

Wong, Karen K. Y. ;

Bennetts, Bruce H. ;

Munns, Craig F. .

HORMONE RESEARCH IN PAEDIATRICS, 2014, 81 (03) :204-210

← 1 2 3 4 5 6 7 8 →